Aton operates as a bioscience company in France. It engages in preclinical and clinical services, production of monoclonal antibodies, and laboratory equipment production, as well as provision of human tissues. The company is involved in development of biomaterials and reagents for diagnostics, as well as preclinical research services. Aton was founded in 1998 and is headquartered in Strasbourg, France.…
Aton : trésorerie tombée à 25 K€ fin juin, des financements recherchés pour 12 mois
Aton (EPA: ALTAO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.0054 EUR on 20 November 2026, down 27.0% over 52 weeks. Its 52-week range is 0.0050 EUR to 0.0290 EUR: the price is 81.4% below the high and 8.0% above the low.
Its market capitalisation is 6.32M EUR.
Aton reports an operating margin of -151.3% and revenue down 22.3% year over year.
Its debt exceeds its cash by 4.10M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.